Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
VOICES (VOICES)

Framework: FP7 — Capacities
Programme: Science in Society
Destination: Science in Society
Action type: Coordination and support actions
Countries involved: Belgium
Call:  (FP7-Adhoc-2007-13, 2007)
Start date: 2013-01-16
End date: 2014-07-15
Duration (months): 18.0
Total project cost (EUR): 1629969.19
EU funding (EUR): 1496624.0
Participants: 1
Project status: CLOSED

VOICES is a Europe-wide public consultation process in the area of urban waste to pilot a methodology and process to involve European citizens in the definition of research priorities. The Ecsite network will host 99 focus groups, involving a total of 990 citizens in all European countries to provide ideas, values, needs and expectations about the theme “Urban waste and innovation”. The results of the consultation will be used by the Consolidation group set up with call SiS.2013.1.2.1-2. The methodology used for the public consultation adheres to the highest academic standards and will be validated by an advisory group. The data from the consultations will be analyzed and aggregated at national and European level; citizens and stakeholders will be able to comment on the results before these are finalized. A series of public events will disseminate the results of the consultations and will highlight the participatory process. Moreover, an on-line tool will document the entire process and will provide open data access to the results of the consultation. The project will be externally evaluated with respect to process and outcomes.

Keywords: public participation,science centers,museums,focus groups,open data,urban waste,rri,science governance,events.
Drug Discovery and Development for Novel Eye Therapeutics (3DNET)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Industry-Academia Partnerships and Pathways
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Ireland,Spain,United Kingdom,Spain,United Kingdom
Call:  (FP7-PEOPLE-2013-IAPP, 2013)
Start date: 2013-09-01
End date: 2017-08-31
Duration (months): 48.0
Total project cost (EUR): 1663674.0
EU funding (EUR): 1663674.0
Participants: 5
Project status: CLOSED

Age-related macular degeneration, diabetic retinopathy, and corneal inflammation are significant causes of irreversible blindness with increasing prevalence as the EU population ages and the “diabetes epidemic” expands. There is an unmet clinical need for more effective treatments to halt or reverse these diseases. Many EU pharmaceutical and biotechnology companies, with established processes for the synthesis and physiochemical characterisation of drugs, have bespoke chemical libraries and lead drugs with potential to treat ocular disease, but lack the expertise and infrastructure to test these drugs in relevant pre-clinical models. In parallel, academic labs with excellent infrastructure to study ocular disease, lack the industry expertise to appropriately develop drugs to enter clinical trials. Thus, clinical development of ocular therapeutics is impeded in the EU due to poor collaboration among academic and industry scientists. 3D-NET establishes a network of industry (Gadea, KalVista & RenaSci) and academic partners (UCD & UVA), who exchange knowledge and people, and who’s combined S&T expertise will enhance the discovery and development of drugs that target ocular pathologies (retinal vessel permeability, unwanted blood vessel growth, inflammation and cell degeneration). Novel ophthalmic drugs will be discovered from unbiased screens of small molecules and developed from hits/leads and selected compounds (PI3K-inhs, lipoxins, Kallikrein-inhs, HDAC-inhs, serotonin agonists), on a set of in silico/in vitro/in vivo/ex vivo preclinical models. Expected outputs are: a) enhancing intersectoral training, career development and trans-national mobility of EU researchers, b) high impact publications/priority patent applications and c) overcoming barriers that impede industry-academia partnership in the EU inhibiting the discovery/development of new-cheaper and more effective drugs for ocular disease.

Keywords: drug discovery,drug screens,drug development,ocular disease,retina,cornea,angiogenesis,vascular permeability,inflammation,cell degeneration,mouse,zerafish
Vaccines and Imaging Partnership (VIP)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Industry-Academia Partnerships and Pathways
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Ireland,Switzerland,Italy
Call:  (FP7-PEOPLE-2013-IAPP, 2013)
Start date: 2014-10-01
End date: 2018-09-30
Duration (months): 48.0
Total project cost (EUR): 1287900.07
EU funding (EUR): 1287900.07
Participants: 3
Project status: CLOSED

There exists an urgent need to advance methods for detection of bacteria in the body, primarily in the context of infectious disease research. Real-time in vivo analysis empowers the investigator with the ability to non-invasively assess bacterial activity over time, as well as host responses to infection and interventions. Optical Imaging (OI) modalities are based on the detection and quantification of bioluminescent or fluorescent light from the subject and represent powerful yet cost-efficient and convenient systems. By labelling of bacteria and/or host cells of interest, both bacterial and host responses can be assessed in rapid, high-throughput analyses, providing spatial, temporal and quantitative read-out, without the need for radioactivity. There is a large and increasing market need for efficient reagents for in vivo bacterial imaging. We aim to develop improved in vivo imaging and ex vivo analysis methods for the study of bacterial infectious diseases and host immune response to infections, to address the current need across the range of fields of infectious disease and vaccine research. A broad skill set is required in this rapidly advancing field, involving exposure to laboratory science, imaging technology, commercialisation of research and industrial processes. By bringing together an international network of leaders in the fields of molecular imaging, infectious disease, vaccine research and industry, we propose to address the current paucity of technology for imaging of bacteria in research animals. Novartis is a world leader in development of vaccines for infectious diseases, and will provide an industrial steer from the project outset. Through combining the various specialities of this IAPP, the proposed work programme will facilitate transfer of knowledge among project partners, promote the development and training of staff in both academia and industry, as well as providing the industry partner with new R&D tools.

Keywords: in vivo imaging
Enlightenment and Innovation, Ensured through Pre Commercial Procurement in Cities (ENIGMA)

Framework: FP7 — Cooperation
Programme: Information and Communication Technologies
Destination: Horizontal Actions
Action type: Combination of CP & CSA
Countries involved: Netherlands,Belgium,Italy,Spain,Norway,Netherlands,Finland,Sweden,Germany,Netherlands,France
Call:  (FP7-ICT-2013-10, 2013)
Start date: 2013-10-01
End date: 2016-09-30
Duration (months): 27.0
Total project cost (EUR): 5400143.0
EU funding (EUR): 3992412.0
Participants: 16
Project status: CLOSED

Through the ENIGMA project, 5 cities from Sweden, Finland, Italy,The Netherlands and Norway will initiate a joint Pre-Competitive Procurement process leading to the procurement of innovative solutions and radical improvements for these and other cities’ urban safety and energy efficiency using next generation ICT applications in the context of innovative public lighting systems in part of their city fabric. They will be working with and supported by a range of knowledge and networking partners. ENIGMA will bring together procurers and experts from 9 European countries as well as a wider group of associate cities and partners from several more EU member states to learn and contribute to the PCP process. The project aims at bringing radical improvements to the quality and efficiency of public services (local and national) by supporting the development and validation of breakthrough solutions through a joint Pre-Commercial Procurement process. This objective will be reached through the following types of activities: 1. Joint analytical and learning activities related to the PCP process and procedures, and 2. The development of new, innovative ICT solutions finding their application in public lighting application with a view to enhance urban safety and improve energy consumption, procured through a joint transnational PCP process; 3. Networking, coordination and EU wide awareness raising activities related to PCP. ENIGMA will focus on PCP in connection to the theme of lighting. Solutions for urban public lighting applications will be linked to the following sub-themes, both important societal challenges in European cities today, each of which will be addressed through a series of different project activities: • Security and urban safety • Energy efficiency The project will cover the full PCP life cycle of solution design, prototyping, and original development of a limited volume of products/services in the form of a test series executied in the 5 pilot cities.

Keywords: innovation public lighting urban safety energy efficiency
Research and Development in Coal-fired Supercritical Power Plant with Post-combustion Carbon Capture using Process Systems Engineering techniques (R-D-CSPP-PSE)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: International Research Staff Exchange Scheme
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: United Kingdom,United Kingdom,France
Call:  (FP7-PEOPLE-2013-IRSES, 2013)
Start date: 2014-01-01
End date: 2017-12-31
Duration (months): 48.0
Total project cost (EUR): 352800.0
EU funding (EUR): 352800.0
Participants: 4
Project status: CLOSED

The proposed joint exchange programme on Coal-fired Supercritical Power Plant with Post-combustion Carbon Capture using chemical absorption is to develop and maintain long term collaborations between European and Chinese universities by carrying out joint research in process model development, process analysis, operation, controller design and optimisation for reliable and optimal design, operation and control of coal-fired supercritical power plant integrated with post-combustion carbon capture through individual mobility of researchers between Europe and China. There are 7 partners involved (four from Europe and another three from China). These partners are world leading in their respective research areas. The project is planned to start from 1 Jan. 2014 and continue for 48 months. There will be 21 experienced researchers and 19 early stage researchers participating in the joint research programme with exchange visits of 168 man months. The resources of €352,800 will be requested from this Europe Union Marie Curie Action to support these exchange visits. The European partners are experts at heat transfer, carbon capture plant modelling and simulation, CFD studies, process control and monitoring, whilst the Chinese partners are experts at coal-fired supercritical power plants, synthesis of solvents for carbon capture based on molecular design, molecular simulation, process control and optimisation. Mutual transfer of knowledge and skills will take place through these exchange visits. Successful completion of the proposed joint research programme will help build long term collaborations in clean coal technologies between Europe and China. It will also publish 30 Journal papers and 50 Conference papers. Three special sessions in major international conferences in 2015, 2016 and 2017 will be organised to disseminate the research results obtained from this joint research programme.

Keywords: post-combustion carbon capture,coal-fired supercritical power plant,process systems engineering,process modelling,simulation and optimisation,process control
Small molecules activating RET for the treatment of Parkinson's disease (GDNF MIMETICS)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Industry-Academia Partnerships and Pathways
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Finland,Estonia
Call:  (FP7-PEOPLE-2013-IAPP, 2013)
Start date: 2013-11-01
End date: 2017-10-31
Duration (months): 48.0
Total project cost (EUR): 870268.0
EU funding (EUR): 870268.0
Participants: 2
Project status: CLOSED

Parkinson’s disease (PD) is caused by degeneration and progressive loss of dopaminergic (DA) neurons of the substantia nigra. In Western countries more than 6 million people live with PD. Currently no cure for this disease is available, existing therapeutic strategies alleviate PD symptoms but do not influence its cause or in other words do not prevent or slow down degeneration of DA neurons. Glial cell line-derived neurotrophic factor (GDNF) is one of the few molecules able to protect and repair DA neurons in animal models of PD. GDNF protein and the related factor neurturin were tested in five clinical trials, but the results have been inconclusive. The pharmacokinetic properties of these proteins complicate their therapeutic development. They do not pass blood-brain-barrier (BBB). Moreover, these factors diffuse poorly from the site of injection. The purpose of current proposal is to combine expertises of the academic and industrial partner in the fields of computational/medicinal chemistry (industrial participant), molecular/behavioural neuroscience and neuropharmacology (academic participant) to develop small molecules passing BBB and efficiently protecting and repairing dopaminergic neurons in vivo. We have developed an initial set of hits that activate GDNF receptors that at 1-10 uM concentration protect and repair DA neurons in vitro. We plan to optimize existing molecules and develop new ones to achieve an active concentration in the range 1-10nM using rational drug design approaches and cell-based screening methods developed by us. Successful compounds will be tested and optimized for ADMET and pharmacokinetic properties and studied in rat models of Parkinson’s disease to determine their safety, efficacy and other pharmacological characteristics. The expected outcome of this project is generation of safe drug-candidates efficient against Parkinson’s disease manifestations in laboratory animals.
Exploitation of microbial biodiversity for the discovery and development of novel cosmeceutical agents (MICROSMETICS)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Industry-Academia Partnerships and Pathways
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Greece,France,Spain,France,Spain,Spain
Call:  (FP7-PEOPLE-2013-IAPP, 2013)
Start date: 2013-11-01
End date: 2017-10-31
Duration (months): 48.0
Total project cost (EUR): 2185174.73
EU funding (EUR): 2185174.73
Participants: 8
Project status: CLOSED

MICROSMETICS aims to discover and carry to the stage of development innovative products in the area of cosmeceuticals originating from global biodiversity using emerging and state of the art technologies in the field of biotechnology, natural products chemistry and applied microbiology. These objectives will be implemented through an extended and balanced scheme of researcher’s exchanges and recruitments, in both directions and via a mutual scientific project developed on the needs and interests of both Industrial and Academic sectors, exploiting the existing complimentary expertise. More specifically, MICROSMETICS scientific concept involves the discovery of novel natural products originating from global microbial biodiversity. Already existing culture collections will be exploited incorporating modern high throughput platforms (in silico & in vitro) for the rational and targeted selection of the most promising strains. Advanced analytical approaches and techniques will be applied for the efficient, accelerated and advantageous isolation and identification of natural constituents as well as the quality assessment of the lead products. A broad spectrum of bioassays and novel analytical approaches will be incorporated for the evaluation of anti-ageing, more specifically anti-oxidant, skin-protecting, and skin-whitening activity of all derived products. Attention will be given to the selection and optimisation of fermentation technologies used for the production of final lead products to ensure sustainability. Within this frame, core scientific knowledge and lead compounds for further development are expected to be produced creating valuable synergies. Expertise will be transferred by means of the seconded researchers training in environments with different dynamics and orientation. MICROSMETICS aspires to comprise a successful model of long-lasting collaboration between Industry and Academia for sustainable exploitation of existing know-how and produced knowledge.

Keywords: natural products,bioactive compounds,microorganisms,cosmeceuticals
Carbon-nanotube-based terahertz-to-optics rectenna (CANTOR)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: International Research Staff Exchange Scheme
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: United Kingdom,Israel
Call:  (FP7-PEOPLE-2013-IRSES, 2013)
Start date: 2014-01-01
End date: 2017-12-31
Duration (months): 48.0
Total project cost (EUR): 91200.0
EU funding (EUR): 91200.0
Participants: 2
Project status: CLOSED

The efficiency of traditional semiconductor solar cells is subject to a fundamental limitation, known as the Shockley-Queisser recombination limit, and is found to be near 30 per cent. The invention in the early eighties of solar cell rectifying antennas (rectennas) - a combination of an optical antenna and a rectifying diode to efficiently absorb the incident solar radiation and directly convert the ac field across the antenna into the dc power - provides a way to overcome the limitation. The recent rapid technological progress in the design of different nano-dimensional structures gives rise to a new promising possibility in designing nanorectennas. A solar cell will incorporate a large array of such elements, which provide high conversion efficiency and can be produced cheaply in a roll-to-roll process. However, a practical realization of such devices requires precise theoretical modelling and experimental study to provide optimization of the antenna and nanocontact configuration. The project focuses on the physics and theoretical modelling of the nanorectenna performance. The rectification effect comes from the photo-assisted charge carrier tunneling through the nanotube energy gap. For the efficiency enhancement we propose using the coherent effect of the photon dressing of electron-hole pairs. Theoretical modelling will be carried out on the basis of the Landauer- Büttiker formalism extended to the case of photon-dressed electrons. The fundamental thermodynamic limitation of the rectenna efficiency and the prospective applications of the device will be studied. This multidisciplinary and challenging project relies on the complementary expertise of the consortium teams and is based on an original approach - nanoelectromagnetics – combining the electrodynamics of mesoscopic inhomogeneous media and quantum transport theory of charge carriers in structures with reduced dimensionality.

Keywords: carbon nanotubes,rectifying antenna
DNA-TRAP – Delivery of Nucleic Acid-Based Therapeutics for the TReatment of Antibiotic-Resistant Pathogens (DNA-TRAP)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Industry-Academia Partnerships and Pathways
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Italy,United Kingdom,Italy
Call:  (FP7-PEOPLE-2013-IAPP, 2013)
Start date: 2013-10-01
End date: 2017-09-30
Duration (months): 48.0
Total project cost (EUR): 2371031.0
EU funding (EUR): 2371031.0
Participants: 6
Project status: CLOSED

Antimicrobial agents, such as antibiotics, have dramatically reduced the number of deaths from infectious diseases over the last 70 years. However, through overuse and misuse of these agents, many micro-organisms have developed antimicrobial resistance. Oligonucleotide therapeutics have the potential to become the new class of antibacterials capable of treating a broad range of infections. By acting on novel targets, they circumvent current resistance mechanisms and with judicious use, can suppress the rise of future resistance. DNA-TRAP will build on a platform technology that uses proprietary nucleic acid-based Transcription Factor Decoys (TFDs) that act on novel genomic targets by capturing key regulatory proteins to block essential bacterial genes and defeat infection. Taking forward newly emerging insights and expertise that exists within each of the partners and through the mutual secondment of researchers, the project aims to develop a new class of nanoparticulate antibacterials capable of meeting the clinical challenge of drug-resistant infections such as Clostridium difficile and Pseudomonas aeruginosa. DNA-TRAP will establish a lasting, international partnership for transfer of knowledge between Industry and Academia in the field of nanomedicine. Exchange of knowledge and expertise between the partners is key to establishing the fundamental properties of nanostructured drug delivery systems to treat bacterial infections and through this, provide the basis for building a manufacturing platform to advance the experimental therapeutic into clinical trials. 17 researchers in the field of drug development and delivery from 2 commercial (SME) and 2 non-commercial partners across 2 member states, will have the opportunity to share and acquire new complementary and multidisciplinary knowledge, through inter-sectoral and interdisciplinary exchange, allowing for the development of new solutions and the establishment of further joint research projects.

Keywords: transcriptional factor decoys (tfd),nanoparticles (np),process development,manufacture,antibacterials,drug development,pseudomonas aeruginosa,clostridium difficile,antibiotic resistance